---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115937"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T02:36:29.777599+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novavax Q3 revenue $735M, net loss $169M; narrows FY 2022 revenue guidance to ~$2.0B

## Summary
- Total revenue $735M (Q3 2021: $179M); net loss $169M vs $322M prior year.
- Cost of sales $435M includes $249M excess/obsolete inventory losses.
- Refines FY 2022 revenue guidance to ~$2.0B, low end of prior $2.0-2.3B range.
- Over 94M doses of COVID-19 vaccine delivered globally; booster authorized in U.S., EU, others.
- Cash and restricted cash $1.3B as of Sept 30, 2022.

## SEC filing metadata
- accession: 0001104659-22-115937
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/0001104659-22-115937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/tm2230063d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115937
- JSON: https://secwatch.observer/filing/0001104659-22-115937.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115937.txt

## Key facts
- Earnings Releases
  NOVAVAX INC reported the third quarter ended September 30, 2022 results: revenue $735 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $735 million
  - Result: reported results
  source text: · Achieved total revenue for the third quarter of $735 million · Delivered over 94 million doses of NVX-CoV2373 globally to date · Authorized as a booster for adults in the U.S., E.U., and additional markets · Authorized as a primary series for adolescents aged 12 – 17 years in U.S., EU, Japan, and additional markets · Announced data about our prototype’s broad immune response against circulating variants when used as a booster · Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of age · Refining full year 2022 total revenue guidance to approximately $2.0 billion · Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., November 8, 2022 – Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/0001104659-22-115937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.